Table 1.
General characteristics of study population.
| Total n = 1062 (%) |
Positive Antibody Response at 3 ± 1 Month N = 556 (%) |
Negative Antibody Response at 3 ± 1 Month N = 506 (%) |
p | |
|---|---|---|---|---|
| Demographic data | ||||
| Age (mean ± SD) (years) | 58.28 ± 13.10 | 56.47 ± 13.61 | 60.26 ± 12.23 | <0.001 |
| Age group | <0.001 | |||
| <39 y | 93 (8.76%) | 63 (67.74%) | 30 (32.26%) | |
| 40–49 y | 156 (14.69%) | 93 (59.62%) | 63 (40.38%) | |
| 50–59 y | 268 (25.24%) | 146 (54.48%) | 122 (45.52%) | |
| 60–69 y | 309 (29.10%) | 148 (47.90%) | 161 (52.10%) | |
| ≥70 y | 236 (22.22%) | 106 (44.92%) | 130 (55.08%) | |
| Sex | 0.967 | |||
| Male | 704 (66.29%) | 368 (52.27%) | 336 (47.73%) | |
| Female | 353 (33.40%) | 185 (52.41%) | 168 (47.59%) | |
| Comorbidities | 0.005 | |||
| No | 347 (32.67%) | 203 (58.50%) | 144 (41.5%) | |
| Yes | 715 (67.33%) | 353 (49.37%) | 362 (50.63%) | |
| Type of graft | <0.001 | |||
| Kidney | 677 (63.75%) | 312 (46.09%) | 365 (53.91%) | |
| Heart | 177 (16.67%) | 86 (48.59%) | 91 (51.41%) | |
| Liver | 182 (17.14%) | 144 (79.12%) | 38 (20.88%) | |
| Lung | 26 (2.45%) | 14 (53.85%) | 12 (46.15%) | |
| Type of vaccine | <0.001 | |||
| BNT162b2 | 928 (87.38%) | 463 (49.89%) | 465 (50.11%) | |
| mRNA-1273 | 134 (12.62%) | 93 (69.40%) | 41 (30.60%) | |
| Time from transplant to vaccination | <0.001 | |||
| Less than 1 year | 58 (5.46%) | 21 (36.21%) | 37 (63.79%) | |
| 1 to 3 years | 166 (15.63%) | 68 (40.96%) | 98 (59.04%) | |
| More than 3 years | 836 (78.72%) | 465 (55.62%) | 371 (44.38%) | |
| Induction regimen in the last 6 months | 0.340 | |||
| No | 1061 (99.90%) | 555 (52.31%) | 506 (47.69%) | |
| Any | 1 (0.09%) | 1 (100%) | 0 (0.00%) | |
| Immunosuppressive drugs at the time of vaccination | ||||
| Calcineurin inhibitors | 1007 (94.82%) | 520 (51.64%) | 487 (48.36%) | 0.046 |
| Tacrolimus | 763 (71.85%) | 384 (50.33%) | 379 (49.67%) | 0.035 |
| Cyclosporine | 246 (23.16%) | 136 (55.28%) | 110 (44.72%) | 0.294 |
| Anti-metabolites | 663 (62.43%) | 284 (42.84%) | 379 (57.16%) | <0.001 |
| Mycophenolate mofetil | 626 (58.95%) | 252 (40.26%) | 374 (59.74%) | <0.001 |
| Azathioprine | 37 (3.48%) | 32 (86.49%) | 5 (13.51%) | <0.001 |
| mTOR | 144 (13.56%) | 90 (62.50%) | 54 (37.50%) | 0.009 |
| Everolimus | 128 (12.05%) | 78 (60.94%) | 50 (39.06%) | 0.038 |
| Sirolimus | 16 (1.51%) | 12 (75.00%) | 4 (25.00%) | 0.068 |
| Steroids | 709 (66.76%) | 312 (44.01%) | 397 (55.99%) | <0.001 |
| Impaired graft function | <0.001 | |||
| Good | 830 (78.15%) | 475 (57.23%) | 355 (42.77%) | |
| Impaired or Failure | 222 (20.90%) | 75 (33.78%) | 147 (66.22%) | |
| Time between first dose and assessment of antibody response | 0.038 | |||
| 40–70 d | 170 (16.01%) | 74 (43.53%) | 96 (56.47%) | |
| 70–100 d | 500 (47.08%) | 262 (52.40%) | 238 (47.60%) | |
| 100–130 d | 298 (28.06%) | 170 (57.05%) | 128 (42.95%) | |
| 130–160 d | 75 (7.06%) | 37 (49.33%) | 38 (50.67%) | |
| >160 d | 19 (1.79%) | 13 (68.42%) | 6 (31.58%) |
mTOR: mammalian target of rapamycin; SD: standard deviation.